USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
PROMENTIS PHARMACEUTICALS, INC.
Address:
826 N. Plankinton Ave
Milwaukee, WI
Phone:
N/A
URL:
N/A
EIN:
175323435
DUNS:
794082193
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $508,369.00 1
SBIR Phase II $1,800,000.00 1

Award List:

Development of Compounds Targeting xc- for the Treatment of Schizophrenia

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$508,369.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Schizophrenia is a debilitating disorder that affects almost 1% of the world's population. The burden on the families and caregivers of patients is immense, and the cost of care in the U.S. is gt 60 billion/y. The high costs arise, in part, due to a lack of… More

Targeting System Xc- for the Treatment of Schizophrenia

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$1,800,000.00
Agency:
HHS
Principal Investigator:
Chad E. Beyer – 318-675-4411
Abstract:
DESCRIPTION (provided by applicant): Schizophrenia is a chronic and debilitating disorder that impacts nearly 1% of the world's population. The burden on the families and caregivers of patients is immense, with the cost of care in the United States being greater than 60 billion annually. The… More